Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Exosomes Derived From Mesenchymal Stem Cells Regulating Myotube Cell Atrophy via NF-κB Signaling Pathway

Ke Y., Wang Y.

Laboratory Study on Osteoarthritis, published in Stem Cells Int (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Stem Cells Int (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42027319
PMCID
PMC13102087
DOI
10.1155/sci/3606738

Abstract (original English)

Bone marrow mesenchymal stem cells (BMSCs), with their potential for multidifferentiation and self-replication, are considered effective for repairing damaged tissues. BMSCs can repair and replace damaged tissues by differentiating into effective cells and secreting some cytokines that inhibit inflammation and promote tissue repair. Recent studies suggest that BMSCs' main role in tissue repair may involve the secretion of exosomes (BMSC-Exos). Basic research has shown that exosomes can have significant effects on orthopedic diseases such as osteoarthritis, muscle tissue injury, and fractures by stimulating regeneration and reducing inflammation. However, the effect of exosomes on tumor necrosis factor (TNF-α)-induced muscle atrophy remains unclear. Therefore, this study investigated the mechanism underlying the protective effect of BMSC-Exos on TNF-α-induced C2C12 myotube atrophy. Treatment with TNF-α (20 ng/mL) for 48 h significantly reduced myotube viability and diameter, which were subsequently reversed by treatment with BMSC-Exos. BMSC-Exos treatment suppressed the expression of E3 ubiquitin ligases, including Atrogin‑1/muscle atrophy F‑box and muscle ring‑finger protein‑1 (MuRF-1). Furthermore, it increased the protein expression levels of myoblast determination protein-1 (MyoD) in TNF-α-induced myotubes. BMSC-Exos also decreased the nuclear translocation of nuclear factor

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research